BaseLaunch accelerates the development of promising and innovative healthcare start-ups in two phases. For the second edition of the program, the BaseLaunch team selected ten startups to join Phase I of the program. Today, the team has announced four projects that will proceed to Phase II to advance their solutions and secure further investment.
The four startups will receive funding of up to CHF 250,000 and support from BaseLaunch and its partners. They will also get access to BaseLaunch’s co-working space and fully-equipped shared laboratory. The objective in phase II is to enable the teams to focus on advancing and de-risking their science and further developing their ventures.
The selected startups for phase II include;
Anaveon (BL)- is a spin-off of the University of Zurich and late pre-clinical phase biotech startup focusing on the development of next-generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer. The startup was already supported last year by BaseLaunch and was again selected for the 2019 phase II program.
Pattern Biosciences (BS) – Next generation programmable therapies powered by Synthetic Biology.
Synendos Therapeutics (BE) – the startup is developing a new class of small molecules for the treatment of anxiety and stress-related disorders by modulating the activity of cannabinoid molecules already present in the human body.
The forth beneficiary is currently in stealth mode.
Since BaselArea.swiss launched this initiative in 2017, BaseLaunch has supported 20 start-ups, several of which have successfully raised follow-on financing. In total, over 160 projects from more than 30 countries applied, reaffirming the strong unmet need currently being addressed by BaseLaunch.
Phase 1 registration openBaseLaunch is now accepting applications for 2019-edition phase I. Eligible to apply are startups and projects focusing on therapeutics, or game-changing innovations in diagnostics, medtech or related fields